Dr. Weiskopf received her Ph.D. in 2009 from the Innsbruck Medical University, Austria, where she performed research analyzing post-translational modifications of viral derived epitopes and the influence of aging on modulation of the T cell immune response. Dr. Weiskopf joined Dr. Sette’s lab as a post-doctoral research fellow in 2009 and applied her knowledge of human T cell immune responses to human pathogens to understand the role of T cells in the context of infection with the dengue virus. Dr. Weiskopf has 11 years of experience in studying T cell immunity, of which 6 years specifically dedicated to studying DENV-specific T cell responses. Over the last several years, she established and published a model of human DENV disease using HLA-transgenic mouse strains. In addition, Dr. Weiskopf has led efforts to characterize human DENV-specific CD8+ and CD4+ T cell responses in both samples from areas with endemic dengue infection and following vaccination. Dr. Weiskopf is the lead author of multiple peer-reviewed publications relating to the mapping and characterization of DENV-specific T cell responses. Dr. Weiskopf’s expertise is additionally evidenced by her selection as a speaker to present the results of the LJI DENV program at various national and international conferences.